Spruce Biosciences, INC Form 4 insider transactions

Adrian W Quartel, Chief Medical Officer of Spruce Biosciences, Inc., received 13,000 shares of common stock on July 27, 2026.

Javier B. Szwarcberg, CEO of Spruce Biosciences, Inc., acquired 266 shares of common stock through the company's Employee Stock Purchase Plan.

Douglas Kirk Ways, Interim Chief Medical Officer and Director of Spruce Biosciences, reported significant equity transactions including RSU vesting and stock option repricing.

Spruce Biosciences CEO Javier B. Szwarcberg acquired 4,690 shares of common stock at $4.5305 per share through the company's Employee Stock Purchase Plan.

Spruce Biosciences' President and CFO, Samir M. Gharib, reported the vesting of restricted stock units and subsequent tax-related share withholdings.

Spruce Biosciences CEO Javier Szwarcberg reported RSU vestings and a significant stock option repricing, adjusting exercise prices for certain employee and director options.

Spruce Biosciences has repriced stock options for Director Daniel K. Spiegelman and other eligible personnel, adjusting exercise prices to $104.13 per share following a reverse stock split.

Spruce Biosciences' Executive Chairman, Michael G. Grey, reported changes in his stock option holdings following a reverse stock split and a company-wide option repricing.

Spruce Biosciences has repriced stock options for its President and CFO, Samir M. Gharib, and other eligible employees and directors, lowering the exercise price to $104.13 per share.

SPRUCE BIOSCIENCES, INC. repriced CEO Javier B. Szwarcberg's stock options, lowering the exercise price to $104.13 per share.

Spruce Biosciences reprices director Camilla V. Simpson's stock options to $104.13 per share following a reverse stock split, aiming to align incentives.

Spruce Biosciences director Percival Barretto-Ko's stock options were repriced to $104.13 per share following a reverse stock split and a company-wide option repricing.

Spruce Biosciences director Keli Walbert was granted 3,400 stock options with an exercise price of $88.41, vesting over three years.

SPRUCE BIOSCIENCES' President and CFO, Samir M. Gharib, reported the vesting of restricted stock units and related common stock transactions, including tax withholdings, on December 10 and 11, 2025.

Spruce Biosciences CEO Javier Szwarcberg reported the vesting of restricted stock units and subsequent tax-related share dispositions, alongside a new RSU grant.

Spruce Biosciences' President and CFO, Samir M. Gharib, vested 2,053 performance-based Restricted Stock Units after the Board certified performance goals were met, resulting in a net issuance of 1,392 shares.

SPRUCE BIOSCIENCES CEO Javier B. Szwarcberg acquired 3,245 net shares of common stock following the vesting of performance-based Restricted Stock Units.

Parkman Healthcare Partners LLC and Gregory Martinez reported recent transactions in Spruce Biosciences, Inc. common stock, including both acquisitions and disposals.

Parkman Healthcare Partners LLC reported both acquisitions and disposals of Spruce Biosciences common stock, adjusting its indirect beneficial ownership.

Spruce Biosciences, Inc. Director Daniel K. Spiegelman was granted 30,000 stock options with an exercise price of $0.1162, vesting over time and upon certain conditions.

Camilla V. Simpson, a Director at Spruce Biosciences, Inc., was granted 30,000 stock options with an exercise price of $0.1162, vesting over time.

Spruce Biosciences, Inc. Executive Chairman Michael G. Grey was granted 30,000 stock options with an exercise price of $0.1162, vesting over time and upon specific events.

Spruce Biosciences, Inc. Director Percival Barretto-Ko was granted 30,000 stock options with an exercise price of $0.1162, vesting over time and upon specific conditions.

Spruce Biosciences Director Tiba Aynechi received a grant of 30,000 stock options with an exercise price of $0.1162, vesting over time and upon specific events.

Spruce Biosciences, Inc. has granted 30,000 stock options to Kirk Ways, its Director and Interim Chief Medical Officer, with an exercise price of $0.1235 per share.

Spruce Biosciences, Inc. director Muralidhar Bali was granted 30,000 stock options with an exercise price of $0.1162, vesting over one year or upon the 2026 annual meeting.

Spruce Biosciences' Chief Medical Officer, Ralph William Charlton III, reports multiple transactions involving the vesting and subsequent tax withholding of restricted stock units (RSUs).

Spruce Biosciences' CFO, Samir M. Gharib, reports the vesting and subsequent transactions of restricted stock units (RSUs), resulting in changes to his beneficial ownership of company stock.

Spruce Biosciences CEO, Javier B. Szwarcberg, reports the vesting and subsequent transactions of restricted stock units (RSUs) resulting in changes to his beneficial ownership.

Director Kirk Ways acquired 30,000 stock options in Spruce Biosciences, Inc. on May 22, 2024, according to a Form 4 filing.